Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

Nature

Volumn 467, Issue 7315, 2010, Pages 591-595

  Mouquet, Hugo ^a   Scheid, Johannes F ^a,b   Zoller, Markus J ^c   Krogsgaard, Michelle ^d   Ott, Rene G ^a   Shukair, Shetha ^e   Artyomov, Maxim N ^f   Pietzsch, John ^a,g   Connors, Mark ^h   Pereyra, Florencia ^f   Walker, Bruce D ^f   Ho, David D ⁱ   Wilson, Patrick C ^j   Seaman, Michael S ^k   Eisen, Herman N ^f   Chakraborty, Arup K ^f   Hope, Thomas J ^e   Ravetch, Jeffrey V ^a   Wardemann, Hedda ^c   Nussenzweig, Michel C ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g FREIE UNIVERSITÄT BERLIN   (Germany)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; CARDIOLIPIN; EPITOPE; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; VIRUS ENVELOPE PROTEIN;

ANTIBODY; CHEMICAL BINDING; ENZYME ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; MOLECULAR ANALYSIS;

ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CROSS REACTION; EPSTEIN BARR VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION; ANTIBODY AFFINITY; ANTIGEN ANTIBODY REACTION; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MUTATION; SURFACE PLASMON RESONANCE; TUMOR CELL LINE;

HEPATITIS C VIRUS; HUMAN HERPESVIRUS 4; HUMAN IMMUNODEFICIENCY VIRUS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY REACTIONS; CARDIOLIPINS; CELL LINE, TUMOR; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN HEAVY CHAINS; MUTATION; SURFACE PLASMON RESONANCE;

EID: 77957355961     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09385     Document Type: Article

References (31)

1. Zhu, P. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847-852 (2006).
2. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G. and Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113 (2008).
3. Klein, J. S. et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl Acad. Sci. USA 106, 7385-7390 (2009).
4. Wardemann, H. et al. Predominant autoantibody production by early humanBcell precursors. Science 301, 1374-1377 (2003).
5. Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated frommemory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
6. Tsuiji, M. et al. A checkpoint for autoreactivity in human IgM1 memory B cell development. J. Exp. Med. 203, 393-400 (2006).
7. Tiller, T. et al.Autoreactivity inhumanIgG1memoryBcells.Immunity 26, 205-213 (2007).
8. Zinkernagel, R. M. et al. Virus-induced autoantibody response to a transgenic viral antigen. Nature 345, 68-71 (1990).
9. Michaelides, M. C.&Eisen, H. N. The strange cross-reaction ofmenadione (vitamin K3) and 2,4-dinitrophenyl ligands with amyeloma protein and someconventional antibodies. J. Exp. Med. 140, 687-702 (1974).
10. Chertova, E. et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76, 5315-5325 (2002).
11. Karlsson, G. B., Gao, F., Robinson, J., Hahn, B. and Sodroski, J. Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses. J. Virol. 70, 6136-6142 (1996).
12. Aguilera, I., Melero, J., Nunez-Roldan, A. and Sanchez, B. Molecular structure of eight human autoreactive monoclonal antibodies. Immunology 102, 273-280 (2001).
13. Ichiyoshi, Y. and Casali, P. Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J. Exp. Med. 180, 885-895 (1994).
14. Shibata, R. et al. Neutralizing antibody directed against the HIV-1 envelope glycoproteincancompletely block HIV-1/SIVchimeric virus infections ofmacaque monkeys. Nature Med. 5, 204-210 (1999).
15. Zolla-Pazner, S. Identifying epitopes of HIV-1 that induce protective antibodies. Natl. Rev. 4, 199-210 (2004).
16. KarlssonHedestam,G. B. et al. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nature Rev. Microbiol. 6, 143-155 (2008).
17. Mascola, J. R. HIV/AIDS: allied responses. Nature 449, 29-30 (2007).
18. Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
19. Krogsgaard, M. et al. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature 434, 238-243 (2005).
20. Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
21. Yurasov, S. et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J. Exp. Med. 201, 703-711 (2005).
22. Jay, J. I. et al.Modulation of viscoelasticity and HIV transport as a function ofpHin a reversibly crosslinked hydrogel. Adv. Funct. Mater. 19, 2969-2977 (2009).
23. Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10, 359-369 (1994). (Pubitemid 24141210)
24. Burton, D. R. et al. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc. Natl Acad. Sci. USA 88, 10134-10137 (1991).
25. Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647 (1993).
26. Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100-1108 (1996).
27. Meffre, E. et al. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J. Exp. Med. 199, 145-150 (2004).
28. Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112-124 (2008).
29. Scheid, J. F. et al. A method for identification of HIV gp140 bindingmemory B cells in human blood. J. Immunol. Methods 343, 65-67 (2009).
30. Alam, S. M. et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl Acad. Sci. USA 107, 5972-5977 (2010).
31. Cheskis, B. and Freedman, L. P. Modulation of nuclear receptor interactions by ligands: kinetic analysis using surface plasmon resonance. Biochemistry 35, 3309-3318 (1996).